EPISODIO n. 03 - Gestire i nuovi farmaci, le tossicità e i profili di safety: gli ARSi

Dettagli

In questo podcast parleremo della tossicità e gestione dei nuovi farmaci per il trattamento del tumore della prostata, con particolare focus sugli inibitori del segnale del recettore androgenico (ARSi). Si tratta di agenti largamente utilizzati nel trattamento del carcinoma della prostata in tutti i setting: nell'ormone sensibile metastatico in doppietta con ADT o tripletta con ADT e docetaxel, al setting resistente alla castrazione sia metastatico che non metastatico.



Bibliografia
  1. Armstrong AJ, et al. Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol 2022; 40:1616-1622.
  2. Chi KN, et al; TITAN Investigators. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med 2019; 381:13-24.
  3. Chi KN, et al. Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study. J Clin Oncol 2021; 39:2294-2303.
  4. Davis ID, et al; ENZAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. N Engl J Med 2019; 381:121-131
  5. de Bono JS, et al; COU-AA-301 Investigators. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364:1995-2005.
  6. Fizazi K, et al; COU-AA-301 Investigators. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 20; 13:983-992.
  7. Fizazi K, et al; PEACE-1 investigators. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer PEACE-1: a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design. Lancet 2022; 399:1695-1707.
  8. Fizazi K, et al; ARAMIS Investigators. Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med 2019; 380:1235-1246.
  9. Fizazi K, et al; ARAMIS Investigators. Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide. N Engl J Med 2020; 383:1040-1049.
  10. Freedland SJ, et al. Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer. N Engl J Med 2023; 389:1453-1465.
  11. Hussain M, et al. Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med 2018; 378:2465-2474.
  12. Ryan CJ, et al; COU-AA-302 Investigators. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013; 368:138-148.
  13. Smith MR, et al; ARASENS Trial Investigators. Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. N Engl J Med 2022; 38612:1132-1142.
  14. Smith MR, et al. Apalutamide and Overall Survival in Prostate Cancer. Eur Urol. 2021; 79:150-158.
  15. Sternberg CN, et al; PROSPER Investigators. Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med 2020; 382:2197-2206.
  16. Stockler MR, et al; ENZAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group ANZUP. Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET ANZUP 1304, an International, Randomized Phase III Trial Led by ANZUP. J Clin Oncol 2022; 40:837-846.